Truist Financial
CRSP icon

Truist Financial’s CRISPR Therapeutics CRSP Stock Holding History

Truist Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Sell
4,026
-1,860
-32% -$98K ﹤0.01% 2729
2026
Q1 		$280K Buy
5,886
+1,288
+28% +$67.9K ﹤0.01% 2436
2025
Q4 		$241K Buy
4,598
+1,060
+30% +$63.5K ﹤0.01% 2478
2025
Q3 		$229K Buy
+3,538
New +$203K ﹤0.01% 2475
2022
Q4 		– Sell
-5,996
Closed -$392K – 2589
2022
Q3 		$392K Buy
5,996
+2,699
+82% +$196K ﹤0.01% 1945
2022
Q2 		$200K Sell
3,297
-396
-11% -$23.3K ﹤0.01% 2447
2022
Q1 		$232K Sell
3,693
-423
-10% -$26.6K ﹤0.01% 2460
2021
Q4 		$312K Sell
4,116
-3,978
-49% -$348K ﹤0.01% 2332
2021
Q3 		$906K Buy
8,094
+1,416
+21% +$178K ﹤0.01% 1668
2021
Q2 		$1.08M Sell
6,678
-478
-7% -$58.1K ﹤0.01% 1602
2021
Q1 		$872K Buy
7,156
+345
+5% +$52.1K ﹤0.01% 1671
2020
Q4 		$1.04M Buy
6,811
+2,972
+77% +$351K ﹤0.01% 1454
2020
Q3 		$321K Sell
3,839
-634
-14% -$56.2K ﹤0.01% 1974
2020
Q2 		$329K Sell
4,473
-1,112
-20% -$65K ﹤0.01% 1883
2020
Q1 		$236K Buy
+5,585
New +$288K ﹤0.01% 2016

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Truist Financial's CRSP Position: Q2 2026 in Review

Truist Financial reduced its CRISPR Therapeutics (CRSP) stake by 32% in Q2 2026, selling an estimated $98K and leaving 4,026 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #2729.

Truist Financial first reported a position in CRSP in Q1 2020 and has held it in 15 quarters since. The position peaked at $1.08M in Q2 2021. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Truist Financial held 4,026 shares of CRISPR Therapeutics worth $220K as of Q2 2026.
  • Truist Financial sold 1,860 CRISPR Therapeutics shares in Q2 2026, an estimated $98K.
  • CRISPR Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2729 holding.
  • Truist Financial first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • Truist Financial's CRISPR Therapeutics position peaked at $1.08M in Q2 2021.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.